Contribute Try STAT+ Today

A few months ago, a federal court judge dismissed all claims against more than a dozen generic manufacturers over allegations that their versions of the Zantac heartburn pill may contain a carcinogen. Now, those companies are seeking to recover potentially significant costs from approximately 1,000 people who filed the lawsuits alleging they were harmed by the pills.

In a recently filed motion, the generic companies indicated they plan to submit a request to recover various costs — such as copies of transcripts — that were incurred since the sprawling litigation began in 2019. Although such costs are generally modest, the numerous depositions and court hearings involving multiple companies suggest such expenses may have been sizable, according to experts.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment